Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRocView Video
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investorsView Video

Latest Share Chat

Oxford BioMedica swings to interim loss as costs climb, revenue falls

Thu, 15th Sep 2022 10:16

(Alliance News) - Oxford BioMedica PLC on Thursday reported a swing to interim loss and a decline in interim revenue.

Oxford BioMedica added that it expects revenue in the second half to be broadly in line with the first.

For the six months that ended on June 30, the Oxford, England-based gene and cell therapy company said it swung to a pretax loss of GBP27.4 million from a profit of GBP19.2 million a year ago.

Revenue declined by 21% to GBP64.0 million from GBP81.4 million a year earlier due to a decrease in vaccine batches manufactured for AstraZeneca PLC, partly offset by an "increase in revenue from lentiviral vector and AAV commercial development and manufacturing activities".

Administrative expenses surged to GBP16.5 million from just GBP6.0 million a year earlier, as research and development jumped by 86% to GBP27.3 million from GBP14.7 million.

Chief Executive Officer Roch Doliveux said: "In the first half of 2022 we achieved double-digit revenue growth in our core business and since the start of the year have signed numerous new or expanded partnership deals, including a new AAV deal, resulting in an over 70% increase in the number of customers with whom we work."

Looking ahead, Oxford BioMedica expects similar levels of revenue in the second half of 2022 as what it achieved in the first half. It also anticipates to deliver broadly break-even operating earnings before interest, tax, depreciation and amortisation for the second half of the year.

In the first half, it made an operating Ebitda loss of GBP5.8 million, swinging from an Ebitda of GBP27.1 million a year prior.

Shares were down 0.5% at 455.01 pence each on Thursday morning in London.

By Xindi Wei; xindiwei@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

Related Shares

More News
20 Mar 2024 16:18

EARNINGS AND TRADING: Roadside Real Estate trims Cambridge Sleep stake

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately repor...

5 Mar 2024 17:09

EARNINGS AND TRADING: Harland & Wolff wins major Falklands contract

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reporte...

5 Mar 2024 16:22

Oxford Biomedica shares rise on post-acquisition guidance

(Sharecast News) - Shares in cell and gene therapy specialist Oxford Biomedica were jumping on Tuesday afternoon, after the company updated the market...

5 Mar 2024 08:57

LONDON BROKER RATINGS: Barclays cuts Bank of Ireland to 'equal weight'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

5 Feb 2024 11:34

EnSilica hires new chief financial officer from Oxford Biomedica

(Alliance News) - EnSilica PLC on Monday said it has appointed a new chief financial officer, who will join the company and board in May.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.